SELLAS Life Sciences Group, Inc. SLS Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $107.1M+277% | $71.79M+417% | $44.32M+111% | $25.3M+177% | $28.4M+54.2% | ||
| $111.17M+248% | $75.21M+361% | $49.05M+104% | $29.45M+139% | $31.97M+48.7% | ||
| $1.91M0.0% | $1.91M0.0% | $1.91M0.0% | $1.91M0.0% | $1.91M0.0% | ||
| $114.18M+227% | $78.35M+303% | $51.56M+94.5% | $32.31M+114% | $34.96M+43.1% | ||
| $3.63M-3.3% | $2.95M-15.8% | $2.31M-49.3% | $3.34M-47.3% | $3.76M-49.3% | ||
| $6.46M-6.3% | $7.02M-26.2% | $5.93M-44.2% | $6M-50.2% | $6.89M-52.3% | ||
| $6.77M-6.0% | $7.47M-25.0% | $5.93M-44.2% | $6.16M-49.6% | $7.2M-51.2% | ||
| $18K+100% | $15K+114% | $12K+100% | $10K+100% | $9K+80.0% | ||
| -$283.4M-11.6% | -$274.99M-10.8% | -$267.33M-10.7% | -$260.54M-11.2% | -$253.94M-12.0% | ||
| $107.41M+287% | $70.87M+649% | $45.63M+187% | $26.15M+798% | $27.76M+187% | ||
| $114.18M+227% | $78.35M+303% | $51.56M+94.5% | $32.31M+114% | $34.96M+43.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are SELLAS Life Sciences Group, Inc.'s total assets?
- SELLAS Life Sciences Group, Inc. (SLS) holds $114.2M in total assets, up 226.6% year over year.
- How much debt does SELLAS Life Sciences Group, Inc. have?
- SELLAS Life Sciences Group, Inc. carries $871.0K in total debt against $107.4M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does SELLAS Life Sciences Group, Inc. have?
- SELLAS Life Sciences Group, Inc. holds $107.1M in cash and equivalents.
- Can SELLAS Life Sciences Group, Inc. cover its short-term obligations?
- Its current ratio is 17.22 — current assets exceed current liabilities.
- Where does SELLAS Life Sciences Group, Inc.'s balance sheet data come from?
- Every line is extracted from SELLAS Life Sciences Group, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.